Kynos Therapeutics Announces a First-In-Human Phase I study of its Novel Small Molecule KMO Inhibitor, KNS366, is Underway
May 18, 2023
EDINBURGH UK – Kynos Therapeutics Ltd, a biotechnology company developing a portfolio of first in class kynurenine 3-monooxygenase (KMO) inhibitors, today announces that dosing is